DATA SHEET

1. {PRODUCT NAME (strength pharmaceutical form)}

The title should be the product name. The title should include both the strength and the pharmaceutical form unless more than one dose or format is covered by the data sheet. The product name strength, and pharmaceutical form should be listed for all formats included in the data sheet. Each format should be on a separate line.

However, when referring to the medicine in the data sheet, the strength and the pharmaceutical form do not have to be mentioned with the name. The International Non-proprietary Name (INN) or the usual common name of the active substance should be used when referring to properties of the active substance(s) rather than those of the product.

Strength
The strength should be the relevant quantity for identification and use of the product and should be consistent with the quantity stated in the quantitative composition and in the dosage recommendations. Different strengths of the same medicine should be stated in the same way (eg, 250 mg, 500 mg, 750 mg). The use of decimal points should be avoided where these can be easily removed (eg, 250 microgram, not 0.25 mg). However, where a range of medicines of the same pharmaceutical form includes strengths of more than one unit (eg, 250 microgram, 1 mg and 6 mg), it may be more appropriate in certain cases to state the strengths in the same unit for the purpose of comparability (eg, 0.25 mg, 1 mg and 6 mg). For safety reasons, micrograms and millions (eg, for units) should always be spelled out in full rather than be abbreviated.

Pharmaceutical form
The pharmaceutical form of a medicine should be as described in an approved pharmacopoeia or as agreed with Medsafe. No reference should be made to the route of administration or container unless these elements are part of the standard term or where there is a particular safety reason for their inclusion or where there are identical products, which may be distinguished only by reference to the route of administration or to the container.

In the case of a medicine authorised as a similar biological product, the following statement should be included:
{Product Name is a biosimilar medicine}.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

{Name and strength of the active substance}

<Excipient(s) with known effect>
<For the full list of excipients, see section 6.1.>

Full details of the qualitative and quantitative composition in terms of the active substance(s) and excipients, knowledge of which are essential for proper administration of the medicine, should be provided in section 2 and as appropriate in section 4.3 or 4.4. The same nomenclature as the product
label should be used. Sponsors may use the European “Guideline on the excipients in the label and package leaflet of medicine for human use” when completing this section.

The following standard statement should be included at the end of the section, ie, ‘for full list of excipients, see section 6.1’.
If a diluent is part of the medicine, information should be included in the relevant sections (usually sections 3, 6.1, 6.5 and 6.6).

**Qualitative declaration**
The active substance should be declared by its recommended INN, accompanied by its salt or hydrate form if relevant. If no INN exists, the pharmacopoeial name should be used or if the substance is not in the pharmacopoeia, the usual common name should be used. In the absence of a common name, the exact scientific designation should be given. References to the pharmacopoeial quality should not be included.

**Quantitative declaration**
The quantity of the active substance should be expressed per dosage unit (for metered dose inhalation products, per delivered dose and/or per metered dose), per unit volume, or per unit of weight and should be related to the declaration of strength in section 1.
Quantity should be expressed in an internationally recognised standard term which could be complemented with another term if more meaningful to healthcare professionals.

**Salts and hydrates**
Where the active substance is present in the form of a salt or hydrate, the quantitative composition should be expressed in terms of the mass (or biological activity in International (or other) units where appropriate) of the active moiety (base, acid or anhydrous material), for example ‘60 mg toremifene (as citrate)’ or toremifene citrate equivalent to 60 mg toremifene’.

Where a salt is formed *in situ* during the preparation of the finished product (ie, formed during the mixture of a solvent and powder), the quantity of the active moiety should be stated, with a reference to the *in situ* formation of the salt.

In the case of established active substances in medicines where the strength has traditionally been expressed in the form of a salt or hydrate, the quantitative composition may be declared in terms of the salt or hydrate (eg, ‘60 mg diltiazem hydrochloride’). This may also apply when the salt is formed *in situ*.

**Esters and pro-drugs**
If the active substance is an ester or pro-drug, the quantitative composition should be stated in terms of the quantity of the ester or pro-drug. When the active moiety is an active substance of an already approved medicine, the quantitative composition should also be stated in terms of the quantity of this active moiety (eg, 75 mg of fosphenytoin is equivalent to 50 mg of phenytoin).

**Oral powders for solution or suspension**
The quantity of active substance should be stated per unit dose if the product is a single-dose preparation or otherwise per unit dose volume after reconstitution; a reference to the molar concentration may also be appropriate in some cases.

**Parenterals excluding powders for reconstitution**
For single-dose parenterals, where the total contents of the container are given in a single dose (‘total use’), the quantity of active substance(s) should be stated per presentation (eg, 20 mg etc) not including any overages or overfill. The quantity per ml and the total labelled volume should also be given.

For single-dose parenterals, where the amount to be given is calculated on the basis of the patient’s weight or body surface or other variable (‘partial use’), the quantity of active substance(s) should be stated per ml. The quantity per total labelled volume should also be given. Overages or overfills should not be included.

For multi-dose and large volume parenterals, the quantity of active substance(s) should be stated per ml, per 100 ml, per 1000 ml, etc as appropriate, except for multidose vaccines containing ‘n’ doses of the same dose. In this case, the strength should be expressed per dose volume. Overages or overfills should not be included.
Where appropriate (eg, for X-ray contrast media, and parenterals containing inorganic salts), the quantity of active substance(s) should also be indicated in millimoles. For X-ray contrast media with iodine-containing actives substances, the quantity of iodine per ml should be stated in addition to the quantity of the active substance.

**Powders for reconstitution prior to parenteral administration**

When the product is a powder to be reconstituted prior to administration, the total quantity of active substance in the container should be stated not including overages or overfills, as well as the quantity per ml when reconstituted, unless there are several means of reconstituting, or different quantities used, which result in different final concentrations.

**Concentrates**

The quantity should be stated as the content per ml in the concentrate and as the total content of the active substance. The content per ml when diluted as recommended should also be included unless the concentrate is to be diluted to within a range of different final concentrations.

**Transdermal patches**

The following quantitative details should be given: the content of active substance(s) per patch, the mean dose delivered per unit time, and the area of the releasing surface (eg, ‘Each patch contains 750 micrograms of estradiol in a patch size of 10 cm², releasing a nominal 25 micrograms of estradiol per 24 hours’).

**Multidose solid or semi-solid products**

Quantity of active substance should be stated, where possible, per unit dose, otherwise per gram, per 100 g or percentage, as appropriate.

**Biological medicines**

Where a medicine contains cells or tissues, a detailed description of these cells or tissues and of their specific origin shall be provided, including the species of animal in cases of non-human origin.

**Expression of strength**

The quantity of biological medicines should be expressed in terms of mass units, units of biological activity, or International Units as appropriate for the particular product.

**The biological origin of the active substance.**

The origin of the active substance should be defined briefly. Thus, the nature of any cellular system(s) used for production and, if relevant, the use of recombinant DNA technology should be specified. The entry should take the form: “produced in XXX cells <by recombinant DNA technology>”. The following are examples of the application of this principle:

- “produced in human diploid (MRC-5) cells”
- “produced in Escherichia coli cells by recombinant DNA technology”
- “produced in chick-embryo cells”
- “produced from the plasma of human donors”
- “produced from human urine”
- “produced from <animal>blood”
- “produced from porcine pancreatic tissue”
- “produced from porcine intestinal mucosa”.

**Biosimilars**

Information on biosimilars should be included as required by the Medsafe position statement on biosimilars {see [www.medsafe.govt.nz/profs/RIs/Biosimilars.asp](http://www.medsafe.govt.nz/profs/RIs/Biosimilars.asp)}.

**Special provisions for normal immunoglobulins.**

In the case of normal immunoglobulins, the IgG subclass distribution should be stated in terms of percent of total IgG present. The upper limit of the IgA content should follow.

**Special provisions for vaccines.**

In the case of vaccines, the content of active substance per dose unit (eg, per 0.5 ml) should be stated. Adjuvants, if present, should be stated qualitatively and quantitatively. Residues that are of special relevance (eg, ovalbumin in egg derived vaccines) should be specified.
3. PHARMACEUTICAL FORM

The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.

The score line is not intended for breaking the tablet.

The tablet can be divided into equal doses.

The term used in this section should be the same as the term used in section 1. However, where a short standard term of a pharmacopoeia is used on small immediate packaging material, the short term should be added in brackets in this section.

A visual description of the appearance of the product (colour, markings, etc) should be given, in a separate paragraph to the standard term, including information on the actual size of a solid oral formulation (eg, ‘Tablet: White, circular flat bevelled-edge tablets of 5 mm marked ‘100’ on one side.’)

Information on pH and osmolarity should be provided, as appropriate.

In case of products to be reconstituted before use, the appearance before reconstitution should be stated in this section. Appearance of the product after reconstitution should be stated in sections 4.2 and 6.6.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

This medicine is for diagnostic use only.

{X} is indicated in <adults> <neonates> <infants> <children> <adolescents> <aged {x to y}> <years> <months>.

The indication(s) should be stated clearly and concisely and should define the target disease or condition distinguishing between treatment (symptomatic, curative or modifying the evolution or progression of the disease), prevention (primary or secondary) and diagnostic indication. When appropriate the target population should be defined especially when restrictions to the patient populations apply.

Study endpoints should not normally be included, unless such mention is appropriate for the indication. The objective of a prevention indication may be mentioned in general terms only. This should also be done for the target population.

Where results from subsequent studies provide further definition or information on an authorised indication, such information, provided it does not itself constitute a new indication, may be considered for inclusion in section 5.1.

Mandatory conditions of product usage not covered more appropriately in other parts of the data sheet may also be included when relevant (eg, concomitant dietary measures, lifestyle changes, or other therapy).

It should be stated in which age groups the product is indicated, specifying the age limits (eg, ‘X is indicated in <adults><neonates><infants><children> <adolescents> <aged x to y> <years, months>).

If the product’s indication depends on a particular genotype or the expression of a gene or a particular phenotype, this should be stated in the indication.

4.2 Dose and method of administration

In case of restricted medical prescription, this section should be started by specifying the conditions.

In case of specific safety need, any recommended restriction to a particular setting should also be
stated (eg, “restricted to hospital use only” or “appropriate resuscitation equipment should be available”). Include any restriction on use for section 23 medicines here and cross reference with 5.1.

Non-interchangeable medicines and medicines that have the potential for individual differences in bioavailability

Include advice regarding switching between formulations and the need for individual patient monitoring if switching is unavoidable.

### Dose

The dosage should be clearly specified for each method/route of administration and for each indication, as appropriate. Reference should only be made to doses which can be delivered using the approved strengths (including whether tablets can be halved). Where appropriate, a reference to official recommendations should be made (eg, for primary vaccination and antibiotics as well as for booster dose).

Dose recommendations (eg, mg, mg/kg, mg/m) should be specified per dose interval for each category where appropriate (specify age/weight/body surface area of subsets of the population as appropriate). Frequency of dosing should be expressed using time units (eg, once or twice daily or every 6 hour) and, to avoid confusion, abbreviations (eg, OD or BID) should not be used.

Where appropriate, the following points should be addressed:

- the maximum recommended single, daily and/or total dose
- the need for dose titration
- the normal duration of use and any restrictions on duration and, if relevant, the need for tapering off, or advice on discontinuation
- advice on action to be taken if one or more dose(s) is (are) missed, or for example in case of vomiting, the advice should be as specific as possible, taking into consideration the recommended frequency of dosing and relevant pharmacokinetic data
- advice on preventive measures to avoid certain adverse drug reactions (eg, administration of antiemetics) with cross-reference to section 4.4
- the intake of the product in relation to drink and food intake, together with a cross-reference to section 4.5 in case of specific interaction (eg, with alcohol, grapefruit or milk)
- advice regarding repeat use, with any information on intervals to be observed between courses of treatment, as appropriate
- interactions requiring specific dose adjustments with cross-reference to other appropriate sections (eg, 4.4, 4.5, 4.8, 5.1, 5.2)
- it may also be relevant to recommend not to prematurely discontinue a treatment in case of specific non-serious adverse reaction(s) that are frequent but transient or manageable with dose titration.

Where relevant to the particular product, the following should appear: ‘The potency of this medicine is expressed in <invented name> units. These units are not interchangeable with the units used to express the potency of other <active substance name> preparations’.

[Additional sub-headings such as “Elderly” or “Renal impairment” can be stated if necessary]

### Special populations

Dosage adjustments or other dose related information in specific patient groups should be stated where necessary, in well-defined sub-sections ordered by importance:

- Elderly population; it should be made clear whether or not any dosage adjustment is necessary in any subsets of the elderly population, with cross-reference to other sections providing information in the elderly (eg, 4.4, 4.5, 4.8 or 5.2).
- Renal impairment; the dose recommendation should relate as precisely as possible to the cut-off values for biochemical markers of renal impairment in clinical studies and to the results of these studies;
- Hepatic impairment, specified according to the patients included in studies, for instance ‘alcohol-related cirrhosis’ and the definitions used in the studies, for instance Child-Pugh score/grade of the patients;
- Patients with a particular genotype; with cross-reference to other relevant sections for further
detail as appropriate;
- Other relevant special population (eg, patients with other concomitant disease or overweight
patients).

Advice relevant for dosage adjustment (eg, from monitoring of clinical symptoms and signs, and/or
laboratory investigations, including blood concentrations of the medicine) should be mentioned when
appropriate with cross-reference to other sections where appropriate.

**Paediatric population**

*The <safety> <and> <efficacy> of {X} in children aged {x to y} <months> <years> [or any other
relevant subsets, such as weight, pubertal age, gender] <has> <have> not <yet> been established.*

*No data are available.*

*Currently available data are described in section <4.8> <5.1> <5.2> but no recommendation on a
dosage can be made.*

*{X} should not be used in children aged {x to y} <months><years> [or any other relevant subsets,
such as weight, pubertal age, gender] because of <safety> <efficacy> concern(s).*

*There is no relevant use of {X} in the paediatric population in children aged {x to y} <months>
<years> [or any other relevant subsets, such as weight, pubertal age, gender] <for the indication
of...>*

*{X} is contraindicated in children aged {x to y} <months><years> [or any other relevant subsets,
such as weight, pubertal age, gender] <for the indication of...> (see section 4.3).*

**Paediatric population**

The specific sub-section ‘paediatric population’ should always be included and the information given
should cover all subsets of the paediatric population, using a combination of the possible situations
presented below as appropriate. If the product is indicated in the paediatric population, dosage
recommendations should be given for each of the relevant subsets. The age limits should reflect the
benefit-risk assessment of the available documentation for each subset. If the dose is the same in adults
and children then a statement to this effect is sufficient; the dose does not need to be repeated.

Dose recommendations (eg, mg, mg/kg, mg/m²) should be specified per dose interval for the paediatric
subsets where the product is indicated. Different subsets may require different dosing information. If
necessary, recommendations in preterm newborns should be presented taking into account the more
appropriate age (eg, gestational age or the post-menstrual age).

Depending on the subset, the clinical data and available formulations, the dose will be expressed
according to weight or body surface area (eg, children aged 2-4 years, 1mg/kg bodyweight twice a
day).

When appropriate information on timing of intake of the product should consider children’s daily life
(eg, school or sleep).

Where a product is indicated in children and no adequate paediatric formulation can be developed,
detailed instructions on how to obtain an extemporaneous preparation for an individual patient shall be
included in section 6.6 with a cross-reference in section 4.2.

Doses and method of administration in the various subsets may be presented in a tabulated format.
If there is no indication for the product in some or all subsets of the paediatric population, no dose
recommendation can be made, but available information should be summarised using the following
standard statements (one or combination of several as appropriate):

- The <safety> <and> <efficacy> of X in children aged x to y <months, years> <or any other
relevant subsets (eg, weight, pubertal age, gender)> <has>> <have> not <yet> been established.

One of the following statements should be added:

- <No data are available>

or
Method of administration

<Precautions to be taken before handling or administering the medicine>

<For instructions on <reconstitution> <dilution> of the medicine before administration, see section <6.6> >

Any special precautions related to the manipulation or administration of the product (eg, cytotoxic products) by healthcare professionals (including pregnant healthcare professionals), the patient or carers should be mentioned here under a specific sub-heading (<Precautions to be taken before manipulating or administering the product>), with a cross-reference to section 6.6.

The route of administration and concise relevant instruction for correct administration and use should be given here. Information on instructions for preparation or reconstitution should be placed in section 6.6 ‘Special precautions for disposal of a used medicine and other handling of the product’ and cross-referenced here.

When supportive data are available, information on alternative method(s) to facilitate administration or acceptability should be given as explicitly as possible (eg, possibility of crushing tablet, cutting tablet or transdermal patch, pulverising tablet, opening capsules, mixing with food, dissolution in drinks – specifying if a proportion of the dose can be given) particularly for administration via feeding tubes.

Any specific recommendation for use related to the pharmaceutical form should be explained, for example:

- “the coated tablet should not be chewed because of <bad taste>”
- “the enteric-coated tablet should not be crushed because coating prevents <pH sensitive degradation><irritant effects> on the gut”
- “the coated tablet should not be broken because the coating is intended to ensure a prolonged release (see 5.2)”.

For parenteral formulations, information on the rate or speed of injection or infusion should be provided.

For parenteral formulations in children, especially newborns in whom quite often fluids have to be restricted, it would be useful to have information on maximal concentration that can be safely administered (eg, "no more than X mg of Y/ml of solution").
4.3 Contraindications

Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1 or residues from the manufacturing process should be included, as well as any contraindication arising from the presence of certain excipients.

Lack of data alone should not lead to a contraindication. Where for safety reasons, the product should be contraindicated in a specific population (e.g., paediatric or a subset of the paediatric population), it should appear in this section with a cross-reference to the section giving detailed information on the safety issue. A contraindication in the paediatric population should be listed without a sub-heading.

4.4 Special warnings and precautions for use

The order of warnings and precautions should in principle be determined by the importance of the safety information provided.

The exact content of this section will be different for each product and the therapeutic conditions it is intended to treat. It is however suggested that the following items should be included where relevant to the specific product.

Information on a specific risk should be given in section 4.4 only when the risk leads to a precaution for use or when healthcare professionals have to be warned of this risk. Patient groups in which use of the medicine is contraindicated should be mentioned in section 4.3 only and not be repeated here. The following should be described:

- the conditions, in which the use of the medicine could be acceptable, provided that special conditions for use are fulfilled. (For example: “Liver function should be monitored before initiation of treatment and monthly thereafter”, “Patients should be advised to immediately report any symptoms of depression and/or suicidal ideation”, “Women of childbearing potential should use contraception”, …)
- special patient groups that are at increased risk or are the only groups at risk of experiencing product or product class-related adverse reactions (usually serious or common), for example elderly, children, patients with renal or hepatic impairment (including the degree of impairment (e.g., mild, moderate or severe)), patients having an anaesthetic or patients with cardiac failure (including in this case the NYHA Classification for example). Cross-reference to section 4.8 on
the differential effects in terms of frequency and severity of the specified adverse reaction should be provided

- serious adverse reactions to which healthcare professionals need to be alerted, the situations in which these may occur and the action that may be required (eg, emergency resuscitation)
- if there are particular risks associated with starting the medicine (eg, first dose effects) or stopping it (eg, rebound, withdrawal effects), these should be mentioned in this section, together with the action required for prevention
- any measures which can be taken to identify patients at risk and prevent the occurrence, or detect early the onset or worsening of noxious conditions. If there is a need for awareness of symptoms or signs representing early warning of a serious adverse reaction, a statement should be included
- any need for specific clinical or laboratory monitoring should be stated. Recommendation for monitoring should address why, when and how the monitoring should be conducted in clinical practice. If dose reduction or other dosage adjustment is recommended in such circumstances or conditions, this should be included in section 4.2 and cross-referenced here
- any warnings necessary for excipients or residues from the manufacturing process
- for formulations containing alcohol, information about the ethanol content in the medicine should be included
- any warnings necessary with respect to transmissible agents
- subjects or patients with a specific genotype or phenotype might either not respond to the treatment or be at risk of a pronounced pharmacodynamic effect or adverse reaction. These may arise because of non-functioning enzyme alleles, alternative metabolic pathways (governed by specific alleles), or transporter deficiencies. Such situations should be clearly described if known
- any particular risk associated with an incorrect route of administration (eg, necrosis risk with extravasation of intravenous formulation, or neurological consequences of intravenous use instead of intramuscular use) should be presented, with advice on management if possible.

In exceptional cases, especially important safety information may be included in bold type within a box.

Any adverse reactions described in this section or known to result from conditions mentioned here should also be included in section 4.8.

Specific interference with laboratory tests should be mentioned when appropriate (eg, Coombs test and Beta-lactams). They should be clearly identified with a subheading, (eg, “Interference with serological testing”).

In general, descriptions of warnings and precautions regarding pregnancy and breast-feeding, ability to drive and use machines, and other aspects of interactions should be dealt with in sections 4.6, 4.7 and 4.5, respectively. However in specific cases of major clinical importance it might be more appropriate to describe specific precautionary measures in this section (eg, contraception measures), or when concomitant use of another medicine is not recommended, and with cross reference to section 4.5, 4.6, or 4.7.

### Paediatric population

When the product is indicated in one or more subsets of the paediatric population and there are warnings and precautions for use that are specific to the paediatric population or any subset of the paediatric population, they should be identified under this subheading. Any necessary warning or precaution in relation to long-term safety (eg, on growth, neuro-behavioural development or sexual maturation) or specific monitoring (eg, growth) in the paediatric population should be described.

When long-term safety data are necessary but not yet available, it should be stated in this section. Warnings should be included in case of possible significant or long-lasting impact on children’s daily activities, such as learning ability or physical activities, or in case of impact on appetite or sleep pattern.
4.5 Interaction with other medicines and other forms of interaction

<No interaction studies have been performed.>

This section should provide information on the potential for clinically relevant interactions based on the pharmacodynamic properties and in vivo pharmacokinetic studies of the medicine, with a particular emphasis on the interactions, which result in a recommendation regarding the use of this medicine. This includes in vivo interaction results which are important for extrapolating an effect on a marker (‘probe’) substance to other medicines having the same pharmacokinetic property as the marker.

Overall, section 4.5 should be presented in the simplest possible way to highlight the interactions resulting in a practical recommendation regarding the use of the medicine. Presentation in a tabulated format may help where interactions are numerous and various, such as with anti-viral products.

Interactions affecting the use of this medicine should be given first, followed by those interactions resulting in clinically relevant changes on the use of others.

Interactions referred to in other sections of the data sheet should be described here and cross-referenced from other sections.

The order of presentation should be contraindicated combinations, those where concomitant use is not recommended, followed by others.

The following information should be given for each clinically relevant interaction:

a. Recommendations: these might be
   - contraindications of concomitant use (cross-refer to section 4.3)
   - concomitant use not recommended (cross-refer to section 4.4), and
   - precautions including dose adjustment (cross-refer to sections 4.2 or 4.4, as appropriate), mentioning specific situations where these may be required.

b. Any clinical manifestations and effects on plasma levels and AUC of parent compounds or active metabolites and/or on laboratory parameters.

c. Mechanism, if known. For example, interaction due to inhibition or induction of cytochrome P450 should be presented as such in this section, with a cross-reference to 5.2 where in vitro results on inhibition or induction potential should be summarised.

Interactions not studied in vivo but predicted from in vitro studies or deducible from other situations or studies should be described if they result in a change in the use of the medicine, cross-referring to sections 4.2 or 4.4.

This section should mention the duration of interaction when a medicine with clinically important interaction (eg, enzyme inhibitor or inducer) is discontinued. Adjustment of dosing may be required as a result. The implication for the need for a washout period when using medicines consecutively should also be mentioned.

Information on other relevant interactions such as with herbal medicines, food, alcohol, smoking, or pharmacologically active substances not used for medical purpose, should also be given.

With regard to pharmacodynamic effects where there is a possibility of a clinically relevant potentiation or a harmful additive effect, this should be stated.

In vivo results demonstrating an absence of interaction should only be mentioned here if this is of major importance to the prescriber (eg, in therapeutic area where potentially problematic interactions have been identified such as with anti-retroviral medicines).

If no interaction studies have been performed, this should be clearly stated.

Paediatric population

Interaction studies have only been performed in adults.
Additional information on special populations

If there are patient groups in which the impact of an interaction is more severe, or the magnitude of an interaction is expected to be larger, for example, patients with decreased renal function (in case the parallel pathway is renal excretion), paediatric patients, elderly etc this information should be given here.

If interactions with other medicines depend on polymorphisms of metabolising enzymes or certain genotypes, this should be stated.

Paediatric population

Information specific to a subset of the paediatric population should be given here if there is an indication for the particular age group.

The resulting exposure and clinical consequences of a pharmacokinetic interaction can differ between adults and children, or between older and younger children. Therefore;

- any identified treatment recommendations should be given in relation to concomitant use in the paediatric subset(s) (eg, dose adjustment, extra-monitoring of clinical effect marker/adverse reactions, therapeutic drug monitoring)
- if the interaction studies have been performed in adults, the statement ‘Interaction studies have only been performed in adults’ should be included
- if the extent of an interaction is known to be similar in a paediatric age group to that in adults, this should be stated
- if this is not known, this should also be stated.

The same applies to pharmacodynamic drug interactions.

In cases of food interaction leading to a recommendation on co-administration with a meal or specific food, it should be specified whether this is relevant for paediatric use (especially newborns and infants) whose diet is different (100 % milk in newborns).

4.6 Fertility, pregnancy and lactation

>Pregnancy>
>Breast-feeding>
>Fertility>

[Additional sub-headings such as “Women of childbearing potential”, “Contraception in males and females” can be stated, as appropriate]

General principles

Efforts should be made by the Sponsor to provide the reasons for the recommendations for use in pregnant or lactating women and in women of childbearing potential. This information is important for the healthcare professionals informing the patient.

In the overall assessment, all available knowledge should be taken into account, including clinical studies and post-marketing surveillance, pharmacological activity, results from non-clinical studies, and knowledge about compounds within the same class.

Efforts should be made to update the recommendations for use during pregnancy and lactation on the basis of increasing human experience in exposed pregnancies which eventually supersede the animal data.

In case of contraindication, this should be included in section 4.3.

The following should be mentioned:

Women of childbearing potential / Contraception in males and females

Recommendations on the use of the medicine in women of childbearing potential should be given when appropriate including the need for pregnancy test or contraceptive measures. Where an effective contraception is required for patients or partners of patients during treatment or for a defined period before starting or after ending treatment, the rationale should be included in this section. If
contraceptive measures are recommended, there should also be a cross-reference to section 4.5 (and possibly 4.4) in case of interaction with oral contraceptives.

**Pregnancy**


In general, clinical and non-clinical data should be followed by recommendations. With respect to non-clinical data:

- only conclusions of the reproductive toxicity studies should be included in this section. Further details should be provided in section 5.3.

With respect to clinical data:

- the section should include comprehensive information on relevant adverse events reported in the embryo, the fetus, neonates and pregnant women, when appropriate. The frequency of such events (for example the frequency of birth defects) should be specified when available
- the section should specify the extent of the human experience if no adverse events have been reported in pregnancy.

With respect to the recommendations:

a) Recommendations on the use of the medicine during the different periods of gestation, including the reason(s) for these recommendations, should be given.

b) Recommendations for the management of exposure during pregnancy when appropriate (including relevant specific monitoring such as fetal ultrasound, specific biological or clinical surveillance of the fetus or the neonate) should be given.

Cross-references can be included in sections 4.3, 4.4 and 4.8, as appropriate.

**Breastfeeding**

If available, clinical data should be mentioned (exposed breastfed infants) as the conclusions of kinetic studies (plasma concentrations in breastfed infants, transfer of the active substance and/or its metabolite(s) into human milk…). Information on adverse reactions in nursing neonates should be included if available.

Conclusions from non-clinical studies on the transfer of the active substance and/or its metabolite(s) into milk should be given only if no human data are available.

Recommendations should be given to stop or continue breastfeeding and/or to stop or continue the treatment in cases where treatment or breastfeeding discontinuation is recommended, and the reason should be provided.

**Fertility**

The main information on the possible effects of the medicine on male and female fertility should be included in section 4.6.

This section should include:

a) Clinical data if available.

b) Relevant conclusions from nonclinical toxicity studies, if available. Further details should be included in section 5.3.

c) Recommendations for the use of the medicine when pregnancy is planned but fertility might be affected by treatment.

Cross-references could be included in section 4.3, if appropriate.

If there are no fertility data at all, then this should be clearly stated.

### 4.7 Effects on ability to drive and use machines

<Invented name> has <no or negligible influence> <minor influence> <moderate influence> <major influence> on the ability to drive and use machines.>

<Not relevant.>
On the basis of the pharmacodynamic and pharmacokinetic profile, reported adverse reactions and/or specific studies in a relevant target population addressing the performance related to driving and road safety or using machines, specify whether the medicine has:

a) no or negligible influence
b) minor influence
c) moderate influence or
d) major influence on these abilities.

Other important factors that affect the ability to drive and use machines should be considered if known (e.g., duration of the impairing effect and the development of tolerance or adverse reactions with continued use). For situations c and d, special warnings/precautions for use should be mentioned here (and also in section 4.4 for situation d).

4.8 Undesirable effects

[Sub-headings should be used to facilitate identification of information on each selected adverse reaction and on each relevant special population (e.g., “Summary of the safety profile”, “Tabulated list of adverse reactions”, “Description of selected adverse reactions” (alternatively the subsection could be named with the name of the relevant adverse reaction), “Other special populations”).]

This section should include all adverse reactions from clinical trials, post-authorisation safety studies and spontaneous reporting for which, after thorough assessment, a causal relationship between the medicine and the adverse event is at least a reasonable possibility, based for example, on their comparative incidence in clinical trials, or on findings from epidemiological studies and/or on an evaluation of causality from individual case reports.

Adverse events, without at least a suspected causal relationship, should not be listed in the data sheet.

This section should be regularly reviewed and, if necessary, updated with the aim to ensure appropriate information to health care professionals on the safety profile of the product.

It is important that the whole section is worded in concise and specific language and does not include information such as claims regarding the absence of specific adverse reactions, comparative frequency statements other than as described below, or statements of general good tolerability such as “well tolerated”, “adverse reactions are normally rare”, and so on. Statements on lack of proof of causal association should not be included.

In order to provide clear and readily accessible information, section 4.8 should be structured according to the following recommendations:

a. Summary of the safety profile

b. Tabulated summary of adverse reactions
c. Description of selected adverse reactions
d. <Paediatric population>
e. <Other special population(s)>

a. Summary of the safety profile

The summary of the safety profile should provide information about the most serious and/or most frequently occurring adverse reactions.

If known, it may be helpful to indicate the timing when adverse reactions occur. For example, in order to prevent early discontinuation of a treatment, it may be important to inform about non-serious adverse reactions that are frequent in the beginning of the treatment but may disappear with its continuation. Another example would be to inform about adverse reaction associated with long-term use. Frequencies of cited adverse reactions should be stated as accurately as possible.

The information should be consistent with the Table of Adverse Reactions (see section b). Cross-reference should be made to section 4.4 if relevant risk minimisation measures have been proposed in that section.

An example of an acceptable statement is given below:
At the beginning of the treatment, epigastric pain, nausea, diarrhoea, headache or vertigo may occur; these reactions usually disappear within a few days even if treatment is continued. The most commonly reported adverse reactions during treatment are dizziness and headache, both occurring in approximately 6% of patients. Serious acute liver injury and agranulocytosis may occur rarely (less than 1 case per 1,000 patients).

b. Tabulated list of adverse reactions

A single table (or structured listing) should list all adverse reactions with their respective frequency category. In some cases for common or very common reactions, and when it is necessary for the clarity of the information, frequency figures may be presented in the table.

Separate tables are acceptable in exceptional cases where the adverse reaction profiles markedly differ depending on the use of the product. For example, it might be the case for a product used for different indications (eg, an oncology and a non-oncology indication) or at different doses.

The table should be introduced with a short paragraph stating the source of the safety database (eg, from clinical trials, post-authorisation safety studies or spontaneous reporting). The table should be presented according to the MedDRA system organ classification. The system organ class (SOC) should be presented in the order shown.

SOC LIST

- Infections and infestations
- Neoplasms benign, malignant and unspecified (including cysts and polyps)
- Blood and lymphatic system disorders
- Immune system disorders
- Endocrine disorders
- Metabolism and nutrition disorders
- Psychiatric disorders
- Nervous system disorders
- Eye disorders
- Ear and labyrinth disorders
- Cardiac disorders
- Vascular disorders
- Respiratory, thoracic and mediastinal disorders
- Gastrointestinal disorders
- Hepatobiliary disorders
- Skin and subcutaneous tissue disorders
- Musculoskeletal and connective tissue disorders
- Renal and urinary disorders
- Pregnancy, puerperium and perinatal conditions
- Reproductive system and breast disorders
- Congenital, familial and genetic disorders
- General disorders and administration site conditions
- Investigations
- Injury, poisoning and procedural complications
- Surgical and medical procedures
- Social circumstances

As a general rule, MedDRA terms should be classified according to the most relevant SOC related to the target organ.

A pragmatic approach to the location of terms should be taken in order to make the identification of adverse reactions simpler and clinically appropriate for the reader. For example, it may be helpful on some occasions to use secondary SOC locations of some MedDRA Preferred Terms (PT), or sometimes to use locations that do not strictly accord with the MedDRA architecture. For example, if the PT ‘Liver function test abnormal’, ‘Hepatitis’ and ‘Hepatic encephalopathy’ are to be included in an SmPC, it would be acceptable to include them all under the SOC ‘Hepatobiliary disorders’ instead.
of distributing the reactions among the SOCs ‘Hepatobiliary disorders’, ‘Nervous system disorders’ and ‘Investigations’ as dictated by their primary location in MedDRA.

Adverse reaction descriptions should be based on the most suitable representation within the MedDRA terminology. This will usually be at the PT level, although there may be instances where the use of Lowest Level Terms (LLT) or group terms, such as high-level terms (HLT) may be appropriate. It is acceptable to adapt the names of the MedDRA group terms if this makes their meaning more transparent to the reader (eg, the use of the suffixes NEC and NOS are not appropriate for inclusion in the data sheet). The adverse reaction term should be expressed in natural word order (eg, ‘Interstitial pneumonia’ in preference to ‘Pneumonia interstitial’). It may be appropriate to modify MedDRA terms in other ways in the interests of comprehensibility. The most widely recognised term for a particular condition should be used, for example, the use of ‘Churg Strauss syndrome’ might be more appropriate than the use of ‘Allergic granulomatous angiitis’.

The estimation of the frequency of an adverse reaction depends on the data source (ie, clinical trial, post-authorisation safety study or spontaneous reporting), the quality of data collection and causality evaluation. If the choice of the frequency category is based on different sources, the category representing the highest frequency should be chosen unless a more specific method has been applied and thus resulted in an estimate of clearly higher validity (eg, a pooled analysis across suitable studies).

Sources of data should use population exposed to the doses and treatment duration as recommended in the data sheet.

Within each MedDRA SOC, adverse reactions should be classified according to their frequency of occurrence. Prior to estimating frequency of occurrence of adverse events from systematic studies (clinical trials or other sources), appropriate levels of the MedDRA hierarchy should be used in order to group together clinically related conditions in a meaningful way. For example, if ‘postural dizziness’, ‘exertional dizziness’ and ‘unspecified dizziness’ were each reported by 2% of patients, this might reasonably be represented in the data sheet as ‘Dizziness’ occurring in 6% of patients (assuming that only one report of dizziness applied to each patient). It may also be appropriate to use ad hoc groupings of terms, or to adapt MedDRA group terms if the established MedDRA group terms are not completely suitable (eg, reports of adverse reactions represented as ‘Diarrhoea’, ‘Diarrhoea aggravated’, ‘Loose stools’, ‘Stools watery’, ‘Intestinal hypermotility’ or other might all reasonably be represented as the single term ‘Diarrhoea’). The total number of those cases should be used to estimate the frequency of diarrhoea.

Adverse reactions from clinical trials
Safety data from several studies should be pooled to increase the precision of adverse reaction rates as appropriate without introducing bias (eg, major difference in population characteristics or exposure to the product).

If these data are unavailable or not sufficiently informative, active-controlled data or possibly single-arm or add-on trials databases could be used to estimate frequencies. Frequency should represent crude incidence rates (and not differences or relative risks calculated against placebo or other comparator).

When a common, very common or serious adverse reaction (eg, suicide) also occurs in the placebo group with a relevant frequency, both incidence rates can be stated to put the risk into perspective (eg, in subsection c).

Adverse reactions from safety studies
The choice of the frequency category to which any adverse reaction will be assigned is based on the point estimate of the crude incidence rate derived from a study designed in such a way that specific adverse events occurring in patients within a defined observation period would have been detected and reasonably attributed to the medicine. In this situation, it is possible to calculate a point estimate of the crude incidence rate using standard statistical methods. In cases where the original information is expressed as an incidence density (denominator expressed as person-time), an appropriate transformation into an incidence proportion should be performed for choosing the frequency category. Normally, incidence proportions for the most representative exposure period (eg, 1 week, 3 months, 1 year) should be used to derive the frequency category. However, this may not be appropriate if the hazard function increases over time; in this case, the adverse reaction and its frequency pattern, when clinically relevant, should be properly described in section c).
The frequency category to be chosen for each adverse reaction should not be based on differences calculated against a comparator. However, when data are derived from a study with a non-exposed group and the rate difference attributed to the medicine is smaller than the baseline or background incidence rate, and if the adverse reaction is considered important, the background incidence may be provided (eg, in section c).

**Adverse reactions from spontaneous reporting**

The number of spontaneous reports should not be stated because the number can quickly become outdated. Frequencies based on reporting rates from a spontaneous reporting system should not be used to assign frequency category. In case of an unexpected adverse reaction detected from spontaneous reporting, each adequately designed study where this adverse reaction could have been detected should be reviewed to choose a frequency category. If the adverse reaction has never been observed in clinical trials, then the upper limit of the 95% confidence interval is not higher than 3/X, with X representing the total sample size summed up across all relevant clinical trials and studies (eg, those with a follow-up long enough to detect the adverse reaction). For example, if a particular adverse reaction has not been observed among 3600 subjects exposed to the product in clinical trials and studies, then the upper limit of the 95% confidence interval for the point estimate is 1/1200 or less and the frequency category should be "rare", based on worst value of the point estimate. The rationale for the frequency category for that particular reaction could be explained in sub-section c).

Within each frequency grouping, adverse reactions should be presented in the order of decreasing seriousness. The names used to describe each of the frequency groupings should follow the following convention: Very common (1/10); common (1/100 to <1/10); uncommon (1/1,000 to <1/100); rare (1/10,000 to <1/1,000); very rare (<1/10,000).

In exceptional cases, if a frequency cannot be estimated from the available data, an additional category frequency ‘not known’ may be used. In case the expression “Frequency not known” is used, the following text should be added in the list of terms explaining the frequency categories: ‘not known (cannot be estimated from the available data)’. The expressions isolated/single cases/reports should not be used.

Where additional details about an adverse reaction are described in section c), the reaction concerned should be highlighted, for example with an asterisk, and, “see section c)” should be included as a footnote.

**c. Description of selected adverse reactions**

This section should include information characterising specific adverse reactions which may be useful to prevent, assess or manage the occurrence of an adverse reaction in clinical practice.

This section should include information characterising individual serious and/or frequently occurring adverse reactions, or those where there have been reports of particularly severe cases. The information should provide frequency and may describe for example reversibility, time of onset, severity, duration, mechanism of the reaction (if of clinical relevance), dose relationship, relationship with duration of exposure or risk factors. Measures to be taken to avoid specific adverse reactions or actions to be taken if specific reactions occur should be mentioned under section 4.4 and cross-referenced here.

Information on the occurrence of withdrawal reactions may be mentioned here with cross-reference to section 4.2 in case of need for tapering off or advice on discontinuation of the product.

Mention should be made here of any differences between different dosage forms in respect of adverse reactions. In the case of combination products, information should be included in this sub-section pointing out which particular adverse reactions are usually attributable to which active substance of the combination, where known.

Any adverse reactions resulting directly from an interaction should be mentioned here and cross-referenced to section 4.5.

This section should also inform on adverse reactions with very low frequency or with delayed onset of symptoms which may not have been observed in relation to the product, but which are considered to be related to the same therapeutic, chemical or pharmacological class. The fact that this is a class attribution should be mentioned.
Any adverse reaction specific to excipients or residues from the manufacturing process should be included.

**<Paediatric population>**

d. **<Paediatric population>**
A paediatric sub-section should always be included (unless irrelevant). The extent and age characteristics of the safety database in children should be described (eg, from clinical trials or pharmacovigilance data). Uncertainties due to limited experience should be stated. If the observed safety profile is similar in children and adults this could be stated: (eg, “Frequency, type and severity of adverse reactions in children are <expected> to be the same as in adults”). Similarly, it is appropriate to state whether the safety profiles in the different paediatric subsets are similar or not.

Any clinically relevant differences (ie, in nature, frequency, seriousness or reversibility of adverse reactions) between the safety profiles in adult and paediatric populations, or in any relevant age groups, should be described and presented by age group. If there is a need for specific monitoring, this should be highlighted by cross-referencing to section 4.4.

For clinically relevant differences, a separate table listing such adverse reactions by frequency can be added and presented by relevant age groups if appropriate. If some paediatric adverse reactions are considered common (≥1/100 to <1/10) or very common (≥1/10), the frequencies should be provided in parentheses. In case of major difference with the safety profile in adults, a summary of the safety profile in children could be presented to facilitate the presentation of the information. Available information, from any source scientifically validated, on long-term safety in children (eg, on growth, mental development and sexual maturation) should also be summarised, whether positive or negative, with cross-reference to section 5.1 if appropriate. Any risk factors such as duration of treatment or period at risk should be specified.

If relevant, symptoms of neonatal withdrawal should be listed in a separate paragraph with cross reference with 4.6.

e. **<Other special populations>**
This section may include information on any clinically relevant differences (ie, in nature, frequency, seriousness or reversibility of adverse reactions, or need for monitoring) specifically observed in other special populations such as elderly, patients with renal impairment, patients with hepatic impairment, patients with other diseases or a specific genotype. Cross-reference to other sections such as 4.3, 4.4 or 4.5 may be added as appropriate.

Adverse reactions may also be related to genetically determined product metabolism. Subjects or patients deficient in the specific enzyme may experience a different rate or severity of adverse reactions. This should be mentioned and where relevant correlated with data from clinical trials.

**Reporting of suspected adverse reactions**
Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions [https://nzphvc.otago.ac.nz/reporting/](https://nzphvc.otago.ac.nz/reporting/).

4.9 **Overdose**

Describe acute symptoms and signs and potential sequelae of different dose levels of the medicine based on all available information including accidental intake, mistakes and suicide attempts by patients.

Taking into account all relevant evidence, describe management of overdose in man (eg, in relation to monitoring or use of specific agonists/antagonists, antidotes or methods to increase elimination of the medicine such as dialysis). However, there should not be any dosage recommendation of other medicines (eg, antidotes) as it could create conflict with the data sheets of those other products. If applicable, counteractive measures based on genetic factors should be described.
<Paediatric population>

**Additional information on special populations**
Information specifically observed in special populations such as elderly, patients with renal impairment, patients with hepatic impairment, other concomitant diseases etc.

**Paediatric population**
If there are specific paediatric considerations, there should be a sub-section entitled ‘paediatric population’.
Special mention should be made of those medicines/strength of formulation for which ingestion of only one dose unit by children can cause fatal poisoning.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

## 5. PHARMACOLOGICAL PROPERTIES

Sections 5.1 – 5.3 should normally mention information, which is relevant to the prescriber and to other health-care professionals, taking into account the approved therapeutic indication(s) and the potential adverse drug reactions. Statements should be brief and precise.

The sections should be updated regularly when new information becomes available, especially in relation to the paediatric population.

### 5.1 Pharmacodynamic properties

Pharmacotherapeutic group: {group}, ATC code: {code} <not yet assigned>

Inclusion of the therapeutic subgroup (2nd level of WHO classification) with the 3rd (pharmacological subgroup) or 4th (chemical subgroup) level is recommended.

If an ATC code is not yet available, this should be mentioned as ‘not yet assigned’.

<Mechanism of action>
<Pharmacodynamic effects>
<Clinical efficacy and safety>
<Paediatric population>

It may be appropriate to provide limited information, relevant to the prescriber, such as the main results (statistically compelling and clinically relevant) regarding pre-specified end points or clinical outcomes in the major trials, and giving the main characteristics of the patient population. Such information on clinical trials should be concise, clear, relevant and balanced, and should summarise evidence from relevant studies supporting the indication. The magnitude of effects should be described using absolute figures. (Relative risks or odd ratio should not be presented without absolute figures). In the exceptional cases when clinically relevant information from subgroup or post-hoc analyses is presented, it should be identified as such in a balanced manner reflecting the limited robustness of both positive and negative secondary observations.

Any relevant pharmacogenetic information from clinical studies may be mentioned here. This should include any data showing a difference in benefit or risk depending on a particular genotype or phenotype.

For biosimilars, information from clinical studies regarding the comparability of the product to the reference should be included.
Data Sheet Explanatory Guide January 2016

Paediatric population

The results of all pharmacodynamic (clinically relevant) or efficacy studies conducted in children should be presented under this sub-heading. Information should be updated when new relevant information becomes available. Results should be presented by age or relevant subsets.

When there are data available, but there is no authorised paediatric indication, data should be presented and a cross-reference should always be made to section 4.2 and, as appropriate to 4.3.

In presenting results of studies, particular attention should be given to include the relevant safety data.

For exploratory studies, the results of the main endpoints should be given with the main characteristics of the population studied and the doses used.

When they are available, information and results of confirmatory studies should usually supersede and replace those of exploratory studies. For confirmatory studies, the objectives, the study duration, the doses used (and the formulation used if different from the marketed one), the main characteristics of the patient population studied (including age and numbers of patient), and the main results regarding pre-specified endpoints should be provided, whether positive or negative. If data are considered inconclusive, this should be stated.

The objective and the main results or the conclusion of any specific clinical safety study should also be given.

5.2 Pharmacokinetic properties

Absorption

Distribution

Biotransformation

Elimination

Linearity/non-linearity

Pharmacokinetic/pharmacodynamic relationship(s)

Pharmacokinetic properties of the active substance(s) relevant for the advised dose, strength and the pharmaceutical formulation marketed should be given in this section. If these are not available, results obtained with other administration routes, other pharmaceutical forms or doses can be given as alternative.

Basic primary pharmacokinetic parameters, for instance bioavailability, clearance and half-life, should be given as mean values with a measure of variability.

Pharmacokinetics items, which could be included in this section when relevant, are given below.

a. General introduction, information about whether the medicine is a pro-drug or whether there are active metabolites, chirality, solubility, information on the population in which general pharmacokinetic data were obtained, etc.

b. General characteristics of the active substance(s) after administration of the medicine formulation to be marketed:

- **Absorption**: complete or incomplete absorption; absolute and/or relative bioavailability; first pass effect; Tmax; the influence of food; in case of locally applied medicine the systemic bioavailability; involvement of transport proteins. If available, information on the site of absorption in the gastro-intestinal tract should be stated (as it may be important for administration by enteral feeding tubes).

- **Distribution**: plasma protein binding; apparent volume of distribution per kilogram body weight (l/kg); tissue and/or plasma concentrations; pronounced multi-compartment behaviour; involvement of transport proteins.
Biotransformation: degree of metabolism; which metabolites; activity of metabolites and contribution to effect and toxicity; enzymes involved in metabolism; site of metabolism; results from in vitro interaction studies that indicate whether the new compound can induce/inhibit metabolic enzymes.

Elimination: elimination half-lives, total clearance; inter and/or intra-subject variability in total clearance; excretion routes of the unchanged substance and the metabolites including the relative portion of the hepatic and renal eliminated fraction, involvement of transport proteins.

Linearity/non-linearity: linearity/non-linearity of the pharmacokinetics of the active substance with respect to dose and/or time; if the pharmacokinetics are nonlinear with respect to dose and/or time, the underlying reason for the non-linearity should be presented.

Additional relevant information should be included here.

c. Characteristics in specific groups of subjects or patients

• Variations with respect to factors such as age, weight, gender, smoking status, polymorphic metabolism and concomitant pathological situations such as renal failure, hepatic disease, including degree of impairment. If the influence on pharmacokinetics is considered to be clinically relevant, it should be described here in quantitative terms (cross-reference to section 4.2 when applicable).

d. Pharmacokinetic/pharmacodynamic relationship(s):

• Relationship between dose/concentration/pharmacokinetic parameter and effect (either true endpoint, validated surrogate endpoint or side effect).
• The population studied should be described.

Paediatric population

Results of pharmacokinetic studies in the different paediatric age groups should be summarised, with a comparison to adults if available. If appropriate, the dose producing similar product exposure as in adults could be given. The pharmaceutical form(s) used for pharmacokinetic studies in children should be stated. Uncertainties due to limited experience should be stated.

<Antibiotic specific information>

Data sheets for antibiotic agents should contain the following information in a table.

- Additional properties of the agent such as class and information on concentration-dependent activity
- Susceptibility data

<table>
<thead>
<tr>
<th>Species</th>
<th>Resistance group A/B or C</th>
<th>MIC range for organisms without known resistance mechanisms</th>
</tr>
</thead>
</table>
| Alphabetically in categories
  • Aerobic gram positive
  • Aerobic gram negative
  • Anaerobic
  • other | A= resistance not yet described
  B= resistance 10-50%
  C= inherent resistance or resistance greater than 50% | Only for antibiotic species combinations for which there is clinical relevance |

5.3 Preclinical safety data

<Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.>

<Effects in non-clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use.>
Information should be given on any findings in the non-clinical testing which could be of relevance for
the prescriber, in recognising the safety profile of the medicine used for the authorised indication(s),
and which is not already included in other relevant sections of the data sheet.

If the results of the non-clinical studies do not add to the information needed by the prescriber, then the
results (either positive or negative) need not be repeated here.

The findings of the non-clinical testing should be described in brief with qualitative statements as
outlined in the following example:

- Non-clinical data reveal no special hazard for humans based on conventional studies of safety
pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential and toxicity to
reproduction and development.
- Effects in non-clinical studies were observed only at exposures considered sufficiently in
excess of the maximum human exposure indicating little relevance to clinical use.
- Adverse reactions not observed in clinical studies, but seen in animals at exposure levels
similar to clinical exposure levels and with possible relevance to clinical use were as follows.

Findings of non-clinical studies relevant for use in the paediatric population, including juvenile animals
and peri- or post-natal studies, should be presented with a discussion of their clinical relevance, under
a sub-heading if necessary.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

{Name of the excipient(s)}. [For solutions for injection and biochemical preparations, the nature and
amount of any antiseptic or preservative should be described.]

{None.}

A list should be given of the excipients, expressed qualitatively only. All excipients, which are present
in the product, should be included, even those present in small amounts, such as printing inks.

For transdermal patches, all ingredients of the patch (including the adhesive, release liner and backing
film) should be mentioned.

The active substance itself, residues of substances used during manufacture of the finished product (for
example, solvents, head-space gases or antibiotics in vaccine manufacture), lubricants for prefilled
syringes and constituents of capsule shells for inhalation powders not intended to be taken should not
be included.

However, certain residues such as residues of antibiotic or other antimicrobial agents used in
production that are known allergens with a potential for inducing undesirable effects should be
mentioned in section 4.3 or 4.4 as appropriate.

Excipients should be referred to by their recommended INN if existing, accompanied by the salt or
hydrate form if relevant or by their pharmacopoeial name. If an excipient has neither an INN nor
pharmacopoeial name, it should be described by its usual common name. References to the
pharmacopoeial quality should not be included. E numbers should be given along with the common
name of the excipient where they exist and when necessary for proper use.

The ingredients in excipient mixtures should be listed individually. In cases where the full composition
of a flavour or fragrance is not known to the applicant or is too complex, it may be declared in general
terms (e.g., ‘orange flavour’, ‘citrus perfume’). However, any of the components, which are known to
have a recognised action or effect, should be included.

Ingredients that may or may not be added for the pH adjustment should be followed by the parenthesis
‘(for pH-adjustment)’
Invented names or general descriptive names such as ‘printing ink’ should not be used in place of the common name of an ingredient or of a mixture of ingredients but may be used in conjunction with the name(s) of the ingredient(s), so long as it is clear which ingredients are described by the name.

Chemically modified excipients should be declared in such a way as to avoid confusion with the unmodified excipients (e.g., ‘pregelatinised starch’).

In the case of a product containing a covert marker for the purpose of tracking, tracing and authentication, a general term such as “authentication factor” should be included in the list of excipients instead of the name of the excipient, unless the excipient is one that is known to have a recognised action or effect.

For clarity, it is recommended that each excipient be listed on a separate line. It can be useful to list excipients according to the different parts of the product (e.g., tablet core/coat, capsule contents/shells, etc). For products that are presented in more than one container or in dual-chamber containers, the excipients should be listed per container or per chamber.

Abbreviations for excipients should not be used. However, where justified for space considerations, abbreviations for excipient names may appear on the labelling, on condition that these abbreviations are designated in section 6.1.

6.2 Incompatibilities

<Not applicable.>

<In the absence of compatibility studies, this medicine must not be mixed with other medicines.>

<This medicine must not be mixed with other medicines except those mentioned in section 6.6.>

Information on physical and chemical incompatibilities of the medicine with other products with which it is likely to be mixed or co-administered should be stated. This is particularly important for medicines to be reconstituted and/or diluted before parenteral administration. Significant interaction problems (e.g., sorption of products or product components to syringes, large volume parenteral containers, tubing, in-line filters, administration sets, etc) should be stated.

Statements concerning compatibility of the product with other medicines or devices should not be included in this section but in section 6.6. Statements concerning pharmacological and chemical/physical incompatibilities with food should be included in section 4.5. If appropriate, the standard statement, ‘Not applicable’, should be included.

For certain pharmaceutical forms (e.g., parenterals), either of the following standard statements should be included as appropriate:

- ‘In the absence of compatibility studies, this medicine must not be mixed with other medicines.’
- ‘This medicine must not be mixed with other medicines except those mentioned in section 6.6.’

6.3 Shelf life

<...> <6 months> <...> <1 year> <18 months> <2 years> <30 months> <3 years> <...>

The shelf life should be given for the medicine as packaged for sale and, if appropriate, after dilution or reconstitution or after first opening.

A clear statement of the shelf life should be given, in an appropriate unit of time.

An in-use shelf life may need to be stated for other medicines if development studies have found it to be necessary.

Additionally, if different concentrations need to be prepared (e.g., for use in children), the physicochemical stability throughout the entire concentration range should be stated (e.g., “The stability has been demonstrated between x mg/ml and y mg/ml for t hours/days at 25 ºC and 2-8 ºC”). In case of a paediatric indication, if no age appropriate formulation is available for children but an extemporaneous formulation could be prepared from an existing formulation, relevant physicochemical data on storage and stability should be included here with a cross-reference in sections 6.4 and 6.6.”
In case of specific temporary storage conditions need to be provided to healthcare professionals or patients, for example, for the purpose of ambulatory use (eg, shelf-life 24 months at 2-8°C of which 3 months could be below 25°C), specific additional guidance should be provided as appropriate. Such information should always be based on stability data. In particular, the recommended temperature range and maximum duration of temporary storage should be specified. This guidance may also include the action to be taken after the product has been stored under the temporary storage conditions (eg, discard immediately).

Statements such as “These data are not recommendations for storage” should not be used.

No reference should be made to the container unless there are different shelf lives for different containers. Storage conditions should not be included, except for the storage conditions after opening. Statements such as ‘Do not use after the expiry date’ should not be included.

When a device is supplied together with a medicine, the in-use shelf-life of the device should be given where applicable.

6.4 Special precautions for storage

<For storage conditions after <reconstitution> <dilution> <first opening> of the medicine, see section 6.3.>

For storage of sterile products that have been opened, diluted or reconstituted, a cross-reference should be made to section 6.3.

Note that if a specific storage warning is required, the warning should be consistent between the data sheet, label and CMI.

A warning to keep the product out of the reach and sight of children should not be included in the data sheet.

6.5 Nature and contents of container <and special equipment for use, administration or implantation>

<Not all pack sizes may be marketed.>

Reference should be made to the immediate container using a pharmacopoeial standard term; the material of construction of the immediate container should be stated (‘glass vials’, ‘PVC/Aluminium blisters’, ‘HDPE bottles’); and any other component of the product should be listed (eg, needles, swabs, measuring spoons, syringes inhaler devices, desiccant). The graduation on measuring devices should be explained. The container of any solvent provided with the medicine should also be described. Excessive detail (eg, concerning the colour of the stopper, the nature of the heat-seal lacquer) should usually not be included. For parenteral preparations, when enclosure colour is used to differentiate between the presentations of a product, this should be stated here.

If appropriate, it should be indicated if the container closure is child-resistant.

Examples on the text in this section:

- ‘<Volume> ml suspension in a pre-filled syringe (glass) with plunger stopper (chlorobutyl rubber) with or without needle in pack sizes of 5 or 10.’
- ‘HDPE bottle with a child-resistant closure and a silica gel desiccant. Pack-sizes of 30, 60 or 90 film-coated tablets.’

All pack sizes should be listed. Pack sizes mentioned should include the number of units, number of doses (eg, multi-dose vaccines, inhalers, etc), total weight or volume of the immediate container, as appropriate, and the number of containers present in any outer carton. If appropriate, a standard statement, ‘Not all pack sizes may be marketed’, should be included, in order to alert health professionals to the fact that not all listed pack sizes may be available for prescribing or dispensing. Multiple unit packs for distribution purposes only do not constitute new pack sizes for marketing of the product and should therefore not be included in this section.
6.6 Special precautions for disposal <and other handling>

<No special requirements <for disposal>.>

<Any unused medicine or waste material should be disposed of in accordance with local requirements.>

Instructions for disposal should be included here, if appropriate for the product. Where special precautions for the handling and disposal of certain products such as cytotoxics and some biological products or waste material derived from it are advised, eg, in the case of products containing live organisms, these should be stated in this section, as should, where relevant, the disposal of items which come into contact with the product, such as nappies, or spoons used to administer oral vaccines.

If applicable (eg, for cytotoxics), the following standard statement should be included, ‘Any unused product or waste material should be disposed of in accordance with local requirements.’

If there are no special use or handling instructions for the pharmacist or other healthcare professionals, the standard statement, ‘No special requirements.’ should be included.

Any directions necessary for the accurate preparation of certain products such as cytotoxics and some biological products and/or necessary for the protection of persons including parents or carers preparing or handling the product should be stated.

In section 4.2, instructions on handling of the product by the doctor, other health personnel, or patient should be included, as well as general information concerning the administration of the product (whether administered by the patient or the health personnel). If instructions for use/handling are needed where the medicine has to be prepared before use, eg, where it must be suspended or diluted, this information has to be given here.

For clarity, a cross-reference in section 4.2 to the relevant information in section 6.6 could be included (eg, ‘For instructions on dilution of the product before administration, see section 6.6.’)

It is recommend that only information necessary for the pharmacist or other health personnel to prepare the product for administration to the patient should be included here.

Information on the preparation (eg, the suspension of a powder for injection, or preparing a dilution) of the medicine should be included in section 6.6, regardless of who prepares the product (eg, pharmacist, doctor, other health personnel, patient, parents or carers). In the case of products for reconstitution, the appearance of the product after reconstitution should be stated.

Statements concerning compatibility of the product with other medicines or devices can be given here provided the data have been provided in the dossier.

In the exceptional cases where a product is indicated in children and where no adequate paediatric formulation can be developed (based on duly justified scientific grounds), information on extemporaneous formulation should appear under a sub-heading “Use in the paediatric population” and should cross-refer to the section 4.2. Detailed instructions for the preparation of the extemporaneous formulation from the appropriate “adult” or other “older children” dosage form and additional information on extemporaneous formulations for use in younger children shall be provided and, where appropriate, the maximum storage time during which such preparation will conform to its specifications. When necessary, the required packaging material and storage conditions should be stated here.

Any specific warnings for the handling of the product should be in section 4.4.

Information on risks due to occupational exposure should be included in this section, with reference to section 4.4 or 4.8 if there is information in that section.

7. MEDICINE SCHEDULE

<Classification of the medicine>
8. SPONSOR

{Name and address}
{Telephone}

| The telephone number must not be an international toll call. If a freephone number is included, it must be able to be reached from New Zealand. |

<fax>
<email>

9. DATE OF FIRST APPROVAL

<Date of publication in the New Zealand Gazette of consent to distribute the medicine: {DD month YYYY}>

10. DATE OF REVISION OF THE TEXT

[For new data sheets, this includes the date of first approval of the data sheet]

<DD month YYYY Summary of changes>

| An overview of the last change(s) to the data sheet should be included here. For example, changes to 4.4 to include further information regarding liver function monitoring |